Latest Ratios: P/E Ratio -0.0x · EV/EBITDA N/A · ROE -791.0%. (2017–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2M | $3M | $222M | $1.4B | $4.1B | — | — | — | — |
| Enterprise Value | $2M | $3M | $221M | $1.4B | $4.0B | — | — | — | — |
| P/E Ratio → | -0.05 | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.25 | 1.31 | 312.65 | 356.90 | 528.48 | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -791.0% | -791.0% | -383.8% | -112.4% | -165.2% | — | — | -2280.5% | — |
| ROA | -180.6% | -180.6% | -216.2% | -90.3% | -107.4% | -192.7% | -138.3% | -168.6% | -176.1% |
| ROIC | -845.1% | -845.1% | -456.4% | -343.1% | — | — | — | -1618.0% | — |
| ROCE | -684.6% | -684.6% | -261.7% | -93.6% | -76.7% | — | — | -2136.6% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.10 | 0.10 | 1.65 | 0.27 | 0.10 | — | — | 14.57 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.05 | -1.05 | -0.37 | -1.00 | — | — | 1.73 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -164.49 | -164.49 | -5.72 | -1.54 | -6.45 | -21.69 | -19.33 | -19.25 | -18.63 |
Net cash position: cash ($334005) exceeds total debt ($232147)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.06 | 0.06 | 1.44 | 5.37 | 8.79 | 0.23 | 0.16 | 1.03 | 0.25 |
| Quick Ratio | 0.06 | 0.06 | 1.44 | 5.37 | 8.79 | 0.23 | 0.16 | 1.03 | 0.25 |
| Cash Ratio | 0.04 | 0.04 | 1.25 | 5.24 | 8.63 | 0.23 | 0.06 | 0.59 | 0.13 |
| Asset Turnover | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $163792 | $1M | $2M | $1M | $1M | $1M | $1M | $1M |
Imminent liquidity insolvency risk
Based on reported financial data, SHPH trades at a price-to-book ratio of 0.29, a valuation level that suggests the market is heavily discounting the company's intangible assets due to the extreme uncertainty surrounding its clinical-stage pipeline and the immediate threat of insolvency.
The low P/B multiple is not necessarily an indicator of value, but rather a reflection of the market's skepticism regarding the company's ability to convert its intellectual property into commercialized products. Given the lack of revenue and negative earnings, traditional valuation metrics like P/E or EV/EBITDA are effectively meaningless, leaving investors to focus on the liquidation value of the firm's assets.
As reported in financial statements, SHPH's ROIC has remained consistently negative, reaching -71.9% in 2026Q1, which underscores the company's inability to generate productive returns on the capital deployed into its Ropidoxuridine and Doranidazole clinical development programs.
The persistent decay in return on invested capital is a direct consequence of high R&D spending without corresponding revenue generation. This trend suggests that the company is currently destroying shareholder value through its operational burn, and a turnaround in these metrics is entirely dependent on successful clinical trial outcomes rather than operational efficiency improvements.
According to recent SEC filings, the company's current ratio has deteriorated to 0.30 as of 2026Q1, indicating that current assets are insufficient to cover short-term liabilities and leaving the firm with virtually no margin of safety to navigate unexpected clinical or operational delays.
The rapid decline in liquidity from previous quarters highlights a precarious financial position that necessitates immediate external funding. Investors should monitor the company's ability to secure non-dilutive capital, as the current cash position appears inadequate to sustain the ongoing clinical trial milestones required for long-term viability.
While the company's reported debt-to-equity ratio of 0.10% might appear favorable compared to broader industrial peers, this metric is fundamentally misapplied here as it obscures the firm's inability to access traditional credit markets due to its pre-revenue, high-risk clinical profile.
Relying on low leverage as a sign of financial health is misleading for a clinical-stage biotech firm, as it ignores the reality that the company is forced to rely on dilutive equity financing rather than debt. A more appropriate metric for assessing SHPH's financial risk would be the 'cash runway' or 'burn-to-liquidity' ratio, which better captures the urgency of the company's funding requirements.
Includes 30+ ratios · 8 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SHPH stock.
Shuttle Pharmaceuticals Holdings, Inc.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
Shuttle Pharmaceuticals Holdings, Inc.'s return on equity (ROE) is -791.0%. The historical average is -220.5%.
Based on historical data, Shuttle Pharmaceuticals Holdings, Inc. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.